Immune Response BioPharma, Inc. Press releases1 - 10 of 49 Press Releases
Mar 27, 2015
Immune Response BioPharma, Inc., Today provides an update on REMUNE and announces the FDA has accepted the REMUNE HIV/AIDS vaccine BLA (biologics licensing application) for review for therapeutic treatment in adults with HIV/AIDS.
Mar 02, 2015
Immune Response BioPharma, Inc., Today provides an update on the Remune BLA FDA filing and is in receipt of a refuse to file letter from the agency along with IRBP & the FDA's meeting results which suggests the BLA filing could continue under a.
Feb 10, 2015
Immune Response BioPharma, Inc. Announces REMUNE FDA BLA Assignment PDUFA Goal date of December 22nd 2015 for Therapeutic HIV/AIDS Vaccine
Jan 01, 2015
Immune Response BioPharma, Inc. Posts 2nd Half and Full Year 2014 Results Finishing the Year Strong with REMUNE HIV/AIDS Vaccine BLA FDA Filing
Dec 20, 2014
Immune Response BioPharma, Inc. Files BLA with the FDA for REMUNE HIV/AIDS Vaccine Marketing Approval for Therapeutic HIV/AIDS Vaccination
Nov 04, 2014
Immune Response BioPharma, Inc. Files REMUNE Pediatric HIV/AIDS Phase II Study Protocol with the FDA for Breakthrough Designation
Aug 07, 2014
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization
Jul 28, 2014
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells
Jul 14, 2014
Immune Response BioPharma, Inc. Posts Record 1st Half 2014 Results Blockbuster HIV/AIDS Vaccine REMUNE Set to Become First HIV/AIDS Vaccine to File for FDA BLA Approval & Come to Market.
Jun 20, 2014
Immune Response BioPharma, Inc. Selects Seppic to Supply Incomplete Freund’s Adjuvants (IFA) for REMUNE HIV/AIDS Vaccine Commercialization & Pipeline